UBXN4

UBX domain-containing protein 4 · Q92575 · UBXN4 on Sugi Atlas →

0 patent compounds predicted against UBXN4, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to UBXN4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer PHASE1/PHASE2COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer PHASE1/PHASE2COMPLETED
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer PHASE1/PHASE2COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer PHASE1COMPLETED
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer PHASE1UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
A Natural History Study of Angelman Syndrome nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy nanCOMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing nanRECRUITING
Better Delineation of DDX3X Related Phenotype and Epigenetic Signature. nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Genetic Analysis of Hereditary Disorders of Hearing and Balance nanCOMPLETED
Whole Genome Scan of Extended Families With Familial Vocal Cord Paralysis nanCOMPLETED
Stakeholders of Rare Diseases Informing Values In Neuroethics nanRECRUITING
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Gene Analysis of Parkinson's Disease nanCOMPLETED
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome nanRECRUITING
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism nanCOMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a UBXN4 binder may also engage these)

ProteinNameSimilarity
Q5R4I3 1.000 Q5R4I3 →
Q3ZBU9 1.000 Q3ZBU9 →
Q8VCH8 1.000 Q8VCH8 →
Q5HZY0 0.998 Q5HZY0 →
Q9UNN5 0.976 Q9UNN5 →
P54731 0.974 P54731 →
Q924K2 0.972 Q924K2 →
Q6DKA1 0.971 Q6DKA1 →
Q9DC33 0.969 Q9DC33 →
Q94JZ8 0.968 Q94JZ8 →
P29540 0.968 P29540 →
Q6PFL6 0.968 Q6PFL6 →
Q9NP66 0.968 Q9NP66 →
Q6DG43 0.968 Q6DG43 →
Q7SYJ9 0.968 Q7SYJ9 →
Q9C9X0 0.968 Q9C9X0 →
Q653N3 0.967 Q653N3 →
Q96MW1 0.966 Q96MW1 →
UFL1 E3 UFM1-protein ligase 1 0.966 landscape →
SF3A1 Splicing factor 3A subunit 1 0.966 landscape →
Q96NB3 0.965 Q96NB3 →
P32780 0.965 P32780 →
Q7TN31 0.965 Q7TN31 →
Q8R1N0 0.965 Q8R1N0 →
A1A4I9 0.965 A1A4I9 →
Q9DBA9 0.965 Q9DBA9 →
Q5BK07 0.965 Q5BK07 →
Q5VJS5 0.965 Q5VJS5 →
Q68F60 0.965 Q68F60 →
PRPF3 U4/U6 small nuclear ribonucleoprotein Prp3 0.964 landscape →